VanEck Biotech ETF receives a Hold rating due to mixed outlooks among its top holdings and unattractive valuation metrics. BBH's heavy concentration in Amgen, Gilead Sciences, and Vertex ...
BOSTON--(BUSINESS WIRE)--Market volatility and a challenging economic climate have been met with substantial shifts in how and where ETF investors are allocating their capital, according to the ...
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on 12/20/2011. Passively ...
Brown Brothers Harriman & Co., a global financial services firm, released its “The BBH Select Series – Mid Cap Fund” first quarter investor letter. The fund fell -6.0% in the first quarter on a total ...
Tourmaline Partners provides its clients with flexible, front office trading solutions to meet demand for outsourced trading, expected to grow 45% in 2023[http://] [1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results